期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 14, 期 42, 页码 6437-6441出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.14.6437
关键词
Advanced hepatocellular carcinoma; Chemotherapy; Doxorubicin; Sorafenib
Hepatocellular carcinoma (HCC) commonly occurs in hepatitis B endemic areas, especially in Asian countries. HCC is highly refractory to cytotoxic chemotherapy. This resistance is partly related to its tumor biology, pharmacokinetic properties, and both intrinsic and acquired drug resistance. There is no convincing evidence thus far that systemic chemotherapy improves overall survival in advanced HCC patients. Other systemic approaches, such as hormonal therapy and immunotherapy, have also disappointing results. Recently, encouraging results have been shown in using sorafenib in the treatment of advanced HCC patients. In this review, we concisely summarize the evolution of developments in the systemic therapy of advanced HCC. (c) 2008 The WIG Press. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据